Wellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Wellington Management Group LLP raised its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 26.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 585,594 shares of the company’s stock after purchasing an additional 122,402 shares during the quarter. Wellington Management Group LLP’s holdings in Taysha Gene Therapies were worth $1,013,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of TSHA. Norges Bank bought a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $2,528,000. EntryPoint Capital LLC boosted its stake in Taysha Gene Therapies by 127.5% during the 4th quarter. EntryPoint Capital LLC now owns 61,495 shares of the company’s stock valued at $106,000 after purchasing an additional 34,468 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Taysha Gene Therapies by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company’s stock worth $15,409,000 after purchasing an additional 641,305 shares in the last quarter. LPL Financial LLC purchased a new position in shares of Taysha Gene Therapies in the fourth quarter worth $104,000. Finally, AXQ Capital LP bought a new position in shares of Taysha Gene Therapies during the fourth quarter valued at $39,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Thursday. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Trading Up 6.4 %

Taysha Gene Therapies stock opened at $1.25 on Monday. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $4.32. The company has a market cap of $255.23 million, a P/E ratio of 1.98 and a beta of 0.96. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The business has a 50-day simple moving average of $1.58 and a two-hundred day simple moving average of $1.84.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. The company had revenue of $2.02 million during the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. Analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.